Delivery Order SPE2DB22D3401-SPE2DB25FT5CV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a $2,341.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections, with an ultimate completion date of August 7, 2025. This non-set-aside contract represents a single delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,621.91 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with an ultimate completion date of September 17, 2025. This firm fixed price contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $28,363.85 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...
- The Defense Logistics Agency awarded a $2,348.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Zepbound 5 mg/0.5 ml pen injections, with performance completion targeted for August 4, 2025. The contract, awarded August 1, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $2,657.24 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections. The contract, which is not set-aside and utilizes firm fixed pricing, was awarded on August 12, 2025, with an ultimate completion date of August 13, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Zepbound 15 mg/0.5 mL pen injections valued at $1,143.87. This contract represents a firm fixed-price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical supply vehicle running through December 2026. The delivery order carries no set-aside designation and is to...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $6,481.97 to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price delivery order, with an ultimate completion date of May 5, 2025, will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation. Zepbound is a GLP-1 receptor agonist used for chronic weight management,...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5CVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 ml pen injections on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitive award, made without a set-aside designation, is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, under a firm fixed-price delivery order contract type. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the Defense Health System's procurement of contemporary pharmaceutical therapies for military beneficiary populations. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle operating through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The company's extensive federal contract portfolio demonstrates its established capability to deliver diverse pharmaceutical products competitively through the DLA Medical Supply Chain to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/14/25 |